EZH2 is a well-known oncogene found in solid tumors and has also been identified as a transcription repressor. The role of this EZH2- mediated methylation is two-fold, the scientists discovered.

The critical role of EZH2, an essential epigenetic regulator, in cancer progression and treatment is underscored in this new review article published in Genes & Diseases. The study highlights the ...

The company is also seeking approval for the drug, an EZH2 inhibitor, for the blood cancer follicular lymphoma. Choosing the right software translates directly into better client management ...

T cell-based immunotherapies, including CAR-T cell therapies, have significantly advanced treatment options for lymphomas such as diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).

TAZVERIK ® is a registered trademark of Epizyme Inc., an Ipsen company.

Daiichi Sankyo has a second approval in Japan for Ezharmia, its first-in-class dual EZH1 and EZH2 inhibitor, as a treatment for relapsed or refractory peripheral T-cell lymphoma (PTCL).